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The 5-HT6 receptor is a promising target for cognitive disorders, in particular for Alzheimer's disease
(AD). The high afﬁnity and selective 5-HT6 receptor antagonist idalopirdine (Lu AE58054) is currently in
development for mild-moderate AD as adjunct therapy to acetylcholinesterase inhibitors (AChEIs). We
studied the effects of idalopirdine alone and in combination with the AChEI donepezil on cortical
function using two in vivo electrophysiological methods. Neuronal network oscillations in the frontal
cortex were measured during electrical stimulation of the brainstem nucleus pontis oralis (nPO) in the
anesthetized rat and by an electroencephalogram (EEG) in the awake, freely moving rat. In conjunction
with the EEG study, we investigated the effects of idalopirdine and donepezil on sleep-wake architecture
using telemetric polysomnography. Idalopirdine (2 mg/kg i.v.) increased gamma power in the medial
prefrontal cortex (mPFC) during nPO stimulation. Donepezil (0.3 and 1 mg/kg i.v.) also increased cortical
gamma power and pretreatment with idalopirdine (2 mg/kg i.v.) potentiated and prolonged the effects of
donepezil. Similarly, donepezil (1 and 3 mg/kg s.c.) dose-dependently increased frontal cortical gamma
power in the freely moving rat and pretreatment with idalopirdine (10 mg/kg p.o.) augmented the effect
of donepezil 1 mg/kg. Analysis of the sleep-wake architecture showed that donepezil (1 and 3 mg/kg s.c.)
dose-dependently delayed sleep onset and decreased the time spent in both REM and non REM sleep
stages. In contrast, idalopirdine (10 mg/kg p.o.) did not affect sleep-wake architecture nor the effects of
donepezil. In summary, we show that idalopirdine potentiates the effects of donepezil on frontal cortical
gamma oscillations, a pharmacodynamic biomarker associated with cognition, without modifying the
effects of donepezil on sleep. The increased cortical excitability may contribute to the procognitive effects
of idalopirdine in donepezil-treated AD patients.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During the course of the progressive neurodegeneration in
Alzheimer's disease (AD) multiple neurotransmitter systems areoraster), stevenleiser@gmail.
, nelly-richard@hotmail.com
kov), cbun@lundbeck.com
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Ltd. This is an open access article uaffected. Today, symptomatic treatment for the cognitive deﬁcits in
AD targets either cholinergic (acetylcholinesterase inhibitors;
AChEIs) or glutamatergic (NMDA receptor antagonist, memantine)
transmission, however treatment with a single symptomatic agent
has shown insufﬁcient efﬁcacy (Birks and Harvey, 2006; Raina et al.,
2008; Tan et al., 2014). Therefore, treatment of a disease with a
complex pathophysiology like AD may require the combination of
several therapies, with complementary mechanisms of action.
Modulation of serotonergic signaling has been implicated as a
possible therapeutic strategy for AD (Ramirez et al., 2014; Claeysen
et al., 2015). Indeed, the serotonergic system is involved in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2012; Meneses, 2013; Schmitt et al., 2006) and there is promi-
nent degeneration of serotonergic neurons in AD (Bowen et al.,
1983; Lai et al., 2002; Nazarali and Reynolds, 1992). Of the many
serotonin (5-HT) receptor subtypes, the 5-HT6 receptor has
emerged as a promising new target for the treatment of cognitive
deﬁcits in AD (Ramirez, 2013). This receptor was discovered in 1993
as one of the serotonin receptor superfamily, being positively
coupled to adenylate cyclase via the G-protein GaS (Monsma, Jr.
et al., 1993; Ruat et al., 1993). The near exclusive localization in
the brain combined with expression in areas that mediate cognitive
processing (hippocampus, cortex, striatum) make the 5-HT6 re-
ceptor an attractive target for pharmacotherapy in cognitive dis-
orders (East et al., 2002; Roberts et al., 2002; Hirst et al., 2003;
Parker et al., 2012). In a recent study, we demonstrated by double
in-situ hybridization that the 5-HT6 receptor is located on GABA-
ergic medium spiny neurons in the striatum and on gluta-
matergic pyramidal cells, as well as on subsets of GABA-ergic in-
terneurons, throughout the cortical layers and in the hippocampus
(Helboe et al., 2015). This places the 5-HT6 receptor in a position to
regulate the balance between excitatory and inhibitory signaling
(Dawson et al. 2000, 2001; Chuang et al., 2006; Schechter et al.,
2008), which is important given that in AD patients as well as AD
transgenic animal models, there is evidence for an imbalance be-
tween excitation and inhibition leading to altered activity of
cortical and hippocampal networks (Palop et al., 2006, 2007;
Goutagny and Krantic, 2013). In addition, through effects on
GABA-ergic and glutamatergic signaling, antagonism of the 5-HT6
receptor results in the regulation of several additional neuro-
transmitter systems, e.g. cholinergic and monoaminergic signaling
(Lacroix et al., 2004; Chuang et al., 2006; Schechter et al., 2008;
Dawson, 2011). A wealth of preclinical studies have demonstrated
the procognitive potential of 5-HT6 receptor antagonists and a few
have now transitioned to clinical development for the treatment of
AD (Mitchell and Neumaier, 2005; Fone, 2008; Arnt et al., 2010;
Meneses et al., 2011; Maher-Edwards et al., 2011; Ramirez, 2013;
Wilkinson et al., 2014). The use of a 5-HT6 receptor antagonist as
adjunct therapy to treatment with AChEIs appears a particularly
promising approach for the treatment of AD. Preclinical studies
have suggested that 5-HT6 receptor antagonists potentiate the
procognitive and neurochemical effects of AChEIs (Dawson, 2011;
de Bruin et al., 2011; Marcos et al., 2008; Herrik et al., 2016) and
the potential beneﬁt of this combination treatment has beendemonstrated in two Phase II clinical studies in moderate AD
(Maher-Edwards et al., 2011; Wilkinson et al., 2014). Idalopirdine
(Lu AE58054), a high afﬁnity and selective 5-HT6 receptor antago-
nist, is the most advanced compound in Phase III development for
mild-moderate AD as an adjunctive therapy to AChEIs (Wilkinson
et al., 2014).
Synchronous activity of neuronal networks is critical for
cognitive function and can be measured as neuronal oscillations in
an electroencephalogram (EEG) (Draguhn et al., 2014). Of particular
interest are hippocampal oscillations in the theta (4e8 Hz) fre-
quency range and hippocampal and cortical oscillations in the
gamma (30e90 Hz) frequency range as these are each associated
with multiple aspects of cognitive function (Bland, 1986; Colgin
et al., 2009; Jutras et al., 2009; Nyhus and Curran, 2010; Jensen
et al., 2007). In mild-moderate AD, oscillatory changes that are
most consistently described include a reduction of cortical EEG
power in the alpha and gamma bands and clinical studies have
shown a partial normalization of the oscillatory activity with AChEI
treatment (reviewed by: Babiloni et al., 2013; Basar et al., 2013). In
the laboratory rodent, compounds classically termed cognition
enhancers have been shown to elicit a “ﬁngerprint” of enhanced
theta and gamma oscillations in the cortical EEG (Ahnaou et al.,
2014). In the anesthetized rat, stimulation of the brainstem retic-
ular formation activates an ascending pathway from the nucleus
pontis oralis (nPO), which enhances theta and gamma oscillations
in the hippocampus through stimulation of the medial septum/
diagonal band of Broca (Bland and Oddie, 1998; Vertes, 1981;
Stoiljkovic et al., 2015) and may also increase gamma oscillations
in the prefrontal cortex (PFC) through the subsequent mono-
synaptic excitatory inputs from the hippocampus (Thierry et al.,
2000) as well as parallel thalamocortical projections (Steriade,
1999). In the hippocampus, theta and gamma oscillations evoked
during stimulation of the brainstem reticular formation are sensi-
tive to pharmacological agents with procognitive properties
(McNaughton et al., 2007) such as donepezil (Kinney et al., 1999)
and memantine (Guadagna et al., 2012). In a recent study, we have
demonstrated that the 5-HT6 receptor antagonist idalopirdine po-
tentiates the effects of the AChEI donepezil on oscillatory activity in
the hippocampus during stimulation of the nPO (Herrik et al.,
2016). This may constitute one of the mechanisms through which
the compounds have a coordinated effect on cognition. Due to the
well-established coherence between the dorsal hippocampus and
the medial PFC (mPFC) during brainstem stimulation (Kiss et al.,
M. Amat-Foraster et al. / Neuropharmacology 113 (2017) 45e59 472013), elicited gamma oscillations in the mPFC may represent an
additional read-out to test procognitive compounds. As a novel
approach, we therefore investigated whether cortical gamma os-
cillations elicited by nPO stimulation are sensitive to pharmaco-
logical agents with procognitive properties. The present study
investigates the effects of idalopirdine alone, and in combination
with donepezil, on oscillatory activity in the frontal cortex, using
two distinct in vivo electrophysiological approaches: Neuronal os-
cillations in the mPFC during nPO stimulation in the anesthetized
rat, and spontaneous cortical qEEG in the awake, freely moving rat.
In addition, we studied the effects of both compounds on sleep-
wake architecture in conjunction with the qEEG study as both the
cholinergic and serotonergic systems are known to play a crucial
role in sleep-wake regulation (Monti, 2010; Portas et al., 2000;
Jones, 1993; Hobson et al., 1993).
2. Methods
2.1. Brainstem induced neuronal oscillations in mPFC of the
anesthetized rat
2.1.1. Animals
All experiments were performed in accordance with Danish
legislative guidelines and were approved by The Animal Experi-
mentation Expectorate (Dyreforsøgstilsynet) and Lundbeck's
Institutional Animal Care and Use Committee (IACUC). Male
Sprague-Dawley rats (Charles River) were used in the present
study. Rats (weight 250e400 g) were housed under standard
temperature (22 ± 1.5 C) and humidity (55e65%) controlled lab-
oratory conditionswith food andwater available ad libitum in a 12 h
light/dark cycle (lights on at 06:00 h).
2.1.2. Drugs
Idalopirdine (IDL, Lundbeck) was dosed at 1 or 2 mg/kg in a 5%
glucose vehicle (1 ml/kg). Donepezil (DPZ, synthesized at Lund-
beck) was dosed 60 min after IDL or vehicle (veh) at 0.3 mg/kg or
1mg/kg in 0.9% saline vehicle (1ml/kg). All drugs and vehicleswere
administered intravenously (i.v.) through a femoral vein cannula in
urethane anesthetized rats. The following dosing paradigms were
used in the nPO stimulation assay (treatment 1 followed by treat-
ment 2): veh/veh, veh/DPZ0.3, IDL1/DPZ0.3, IDL2/DPZ0.3, veh/
DPZ1, IDL2/DPZ1 (n ¼ 6e8 per group).
2.1.3. Surgical procedure
Rats were ﬁrst anesthetized with urethane (1.5 g/kg, supple-
mented if needed to reduce spontaneously occurring gamma os-
cillations) with an intraperitoneal (i.p.) injection. Under anesthesia,
a femoral vein cannula (P50 tubing) was inserted and rats were
placed in a stereotaxic frame (Kopf) and kept at 37.5 C via a heating
pad (CMA 150, CMA Microdialysis AB, Denmark). Two small holes
were drilled into the cranium to accommodate a stimulating elec-
trode in the nPO (coordinates relative to bregma in mm (Paxinos
and Watson, 1986): AP (anterior posterior): 8.0 mm, L
(lateral): 1.6 mm, V (ventral): 6 mm) and a recording electrode
in the mPFC (AP: 3.2 mm, L: 0.5 mm, V: 2.5 mm). A platinum
wire was placed in the frontal bone to act as a reference electrode.
2.1.4. Electrophysiological recordings and stimulation
Local ﬁeld potentials (LFP) were recorded using unipolar
stainless steel electrodes (0.125 mm in diameter, Plastics One Inc.,
USA). LFP signals were ampliﬁed and ﬁltered between 0.1 and
100 Hz (50 Hz notch ﬁlter off) (DP-311, Warner instruments,
USA). The ampliﬁed LFP signals were digitalized (CED Micro-
1401-3, Cambridge Electronic Design, UK) and sampled at 1 kHz
for off-line analysis (Spike2 software version 7.10, CambridgeElectronic Design Limited, UK). The nPO was stimulated via a
bipolar concentric tungsten electrode 3in (TM53CCINS, World
Precision Instruments Inc., USA) with 0.3 ms square pulses
delivered over 6 s at 250 Hz, repeated every 100 s (A365R, World
Precision Instruments Inc., USA). Stimulation started at 0.025 mA
for 40 min. To establish baseline amplitude levels, the stimulating
intensity required to elicit gamma rhythm was adjusted to obtain
~50% of the maximal gamma response during stimulation under
control conditions. After a stable baseline of 30 min was estab-
lished, idalopirdine or vehicle was administered and EEG recor-
ded for 60 min before a second dose of donepezil or vehicle was
injected. Only studies where a stable baseline was established
before drug injection were included in the data analysis. Epochs
with high amplitude electrical noise were visually identiﬁed and
manually removed before data analysis. When electrical noise
occurred during the entire experiment, this was categorized as
failed and data were not used. At the end of each experiment, a
200 mA current was applied through the electrodes, rats were
euthanized by cervical dislocation and brains were removed for
veriﬁcation of electrode placement. Only experiments in which
electrodes were correctly placed were included in the data
analysis.
2.1.5. Data analysis
The signal processing of LFP activity was computed in MATLAB,
using functions implemented in the Fieldtrip toolbox (http://www.
ru.nl/fcdonders/ﬁeldtrip/) and the sigTOOL toolbox (http://sigtool.
sourceforge.net/sigtool.html).
2.1.5.1. Pre-processing. The recordings were read into MATLAB and
segmented into epochs from 5 s before stimulation onset to 5 s after
nPO offset. The epochs were baseline corrected, to remove any
standing offset, by subtracting the average amplitude in the pre-
nPO period from the entire epoch. Artefact correction was then
performed for each recording, based on the standard score (zEEG,t)
of each sample:
zEEG;t ¼




xEEG;t  mEEG
sEEG




Any sample with an extreme value, i.e. 15 standard scores from
the mean, was considered an artefact. The artefacts were excluded
from analysis.
2.1.5.2. Spectral analysis and statistics. To investigate the effect of
nPO-stimulation itself and the impact of the treatments, power
spectra were computed using a fast Fourier transform between 1
and 90 Hz with a Hamming window on 5 s epochs. Where relevant,
frequency bands were compared by Wilcoxon signed rank test
(Fig. 1A and B). Further investigation of a treatment effect was
completed by performing a short-time Fourier transform using a
ﬁxed 1 s Gaussian window on each epoch in the frequency interval
1e90 Hz. The treatment response over time was computed using
the average raw power over time before and during each epoch;
pre-stimulation (5e0 s) and during nPO stimulation (the last 5 s
of the 6 s nPO-period were used). To visualize a power change from
baseline, the power was normalized to the 30 min average baseline
power prior to the ﬁrst treatment in each frequency bin for each
individual animal. Subsequently, oscillatory activity was divided
into the 5 main frequency bands: delta; 0e4 Hz, theta; 4e8 Hz,
alpha; 8e13 Hz, beta; 13e30 Hz, gamma; 30e90 Hz and compared
between treatments. The data are expressed as group mean ± SEM.
Data were analyzed by two-way repeated measures ANOVA with
treatment (veh/veh, veh/DPZ0.3, IDL1/DPZ0.3, IDL2/DPZ0.3, veh/
DPZ1, IDL2/DPZ1) as between-subject factor and time as within-
Fig. 1. Effect of electrical stimulation of the nPO alone and in combination with vehicle treatment on oscillations in the mPFC of the anesthetized rat. Power spectra of local
ﬁeld potentials in the mPFC. (A) Average power spectra of the baseline period, before (5e0 s epochs) (red) and during (1e6 s epochs) (blue) nPO stimulation (n ¼ 41). (B) Average
power spectra of the baseline (blue) and 30 min after vehicle administration (green) during nPO stimulation (n ¼ 20).
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SigmaPlot (version 11.0).2.2. qEEG in the frontal cortex of the freely moving rat
2.2.1. Animals
All animal care and experimental procedures complied with
guidance on the care and use of laboratory animals by Lundbeck's
IACUC and the US National Research Council (2011). Male Sprague-
Dawley rats (250e300 g) from Charles River were individually
housed under a 12 h light/dark cycle (lights on at 06:00 h) and
temperature- (21 ± 2 C) and humidity- (60± 10%) control with
chow and water available ad libitum.2.2.2. Drugs
Idalopirdine (IDL, Lundbeck) was dosed at 10 mg/kg, per oral
(p.o.) in 5% HP-Beta-CD (2-hydroxypropyl-beta-cyclodextrin)
vehicle. Donepezil (DPZ, Tocris Biosciences, UK) was dosed 2 h
following either idalopirdine (IDL) or vehicle (veh) at 1 mg/kg or
3 mg/kg, subcutaneously (s.c.) in 5% HP-Beta-CD vehicle. The
following dosing paradigms were used in the EEG study (treatment
1 followed by treatment 2): veh/veh, IDL/veh, veh/DPZ1, IDL/DPZ1,
veh/DPZ3 and IDL/DPZ3 (n ¼ 7e9 per group).2.2.3. Surgical procedure
Stainless-steel screw electrodes for EEG and wire electrodes for
EMG of dorsal neck muscles were implanted in each animal under
anesthesia as described previously (Leiser et al., 2014; Dale et al.,
2014; Vogel et al., 2002; Bastlund et al., 2004). Brieﬂy, bipolar (dif-
ferential) EEG screw electrodes were placed supradural approxi-
mately 2.0 mm anterior and 2.0 mm lateral to bregma bilaterally for
frontal cortical EEG and intrahemispheric at 4.0 mm posterior and
2.0 mm lateral to bregma for fronto-parietal EEG. Electrodes were
connected to a sterile multi-channel telemetric device (TL10M3-
F50-EEE; Data Sciences International, DSI) that was implanted s.c.
on the ﬂank. These transmitters also digitally monitored locomotor
activity (LMA) which was used in sleep staging. LMA counts were
calculated using Dataquest A.R.T software (DSI, St. Paul, Minnesota,
USA) as a function of alterations in transmitter signal strength as the
animal moved through the receptive ﬁeld of the receiver located
beneath the animal's home cage.2.2.4. Polysomnographic EEG recordings
EEG Recordings were started 90 min before the ﬁrst treatment
(~9:00 a.m.; 3 h into light cycle) and continued for up to 120 min
after the second treatment, using Dataquest A.R.T software (DSI) at
a sampling rate of 500 Hz. Ofﬂine, using NeuroScore (DSI), artefacts,
detectable as incongruent periods of non-physiological, electrical
activity, were manually scored as such and removed from analyses.
The main types of artefacts were: i. Movement artefacts typically
traversing all EEG and EMG signals, readily detected by a uniform
(non-chaotic) signal of large amplitude outside the physiological
range (e.g. >500 mV), ii. Line noise (60 Hz) or any continuous, non-
physiological frequency pattern that would be considered noise
from external powered sources, iii. EEG that does not fall within
normal amplitude of operation (e.g. physiological range: typically
greater than 100 mV and less than 500 mV). EEG that drops below
this minimum, or “drop-out”, is typically indicative of a loss of
signal ﬁdelity (e.g. battery low or electrode grounding/wire issue),
whereas EEG that is maintained above this maximum (“maxes
out”), is often caused by an electrode grounding/wire issue. iv. EEG
activity contaminated by cardiac events. Rats that exhibited the
above artefacts either routinely, or for greater than 20% of the time
during a recording, were not included in analyses.
Following artefact correction, sleep stages were assigned
manually for every 10 s epoch using fronto-parietal EEG, EMG and
LMA by conventional methods as previously described (Ivarsson
et al., 2005; Parmentier-Batteur et al., 2012; Leiser et al., 2015).
Brieﬂy, sleep stages were determined using the following criteria:
active wake (less regular, low amplitude EEG with high EMG and
LMA); quiet wake (less regular, low amplitude EEG, with low EMG,
and no LMA); NREM or slow wave sleep (high-amplitude waves
dominated by delta (1e4 Hz), low EMG and no LMA); paradoxical or
REM sleep (stable, low-amplitude waves dominated by theta
(4e8 Hz) with near absent EMG and no LMA). Sleep scoring relied
on a two-part process using an optimized automated detection
algorithm employed by Neuroscore (DSI), with a careful manual
examination of each 10 s epoch for congruity with the above
criteria. The Automated Scoring method is not as reliable or accu-
rate as manual scoring and thus manual scoring was performed on
all recordings. All data were scored into the four sleep stages,
however qEEG data are only shown for active wake in this paper in
order to maximize the likelihood of translatability (Maire et al.,
2013).
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2.2.5.1. EEG data. Gamma spectral power (30e90 Hz) during active
wake state was calculated in NeuroScore (DSI) with a 1 Hz reso-
lution. Heatmaps were created using Matlab (Mathworks). Phar-
macologically induced changes in the EEG were evaluated by
averaging the 10 s epochs constituting the 90 min before the ﬁrst
treatment (‘baseline’) and each 30 min bin post-treatment until
120 min after the second treatment. The time period of 120 min
following donepezil administration was chosen as separate expo-
sure studies indicated clinically relevant plasma exposure of
donepezil within this timeframe (>50 ng/ml in plasma) (Tiseo et al.,
1998). To visualize a power change from baseline, the power was
normalized to the 90 min average baseline power prior to the ﬁrst
treatment in each frequency bin for each individual animal. The
data are expressed as group mean ± SEM. Data were analyzed by
two-way repeated measures ANOVAwith treatment (veh/veh, IDL/
veh, veh/DPZ1, IDL/DPZ1, veh/DPZ3 and IDL/DPZ3) as between-
subject factor and time (4 bins of 30 min each) as within-subject
factor, followed by an LSD post hoc analysis, using SigmaPlot
(version 11.0).
2.2.5.2. Sleep stages. Quantitative analysis of each sleep stage
(REM, NREM, quiet wake and active wake) was calculated as the
percent time spent in each sleep stage during the 120 min after the
second treatment. The REM and NREM onset latencies were
determined as the ﬁrst epoch of REM or NREM, respectively, lasting
greater than 20 s, represented in minutes after the second treat-
ment. As sleep onset did not occur within the 120 min after the
second treatment in all treatment groups, animals were monitored
for up to 240 min to establish REM and NREM onset. Data were
analyzed by one-way ANOVA followed by Bonferroni post-hoc
analysis using SigmaPlot (version 11.0).
2.3. Plasma and brain exposure of idalopirdine and donepezil
2.3.1. Tissue and plasma collection
In the nPO stimulation assay, plasma and brain concentrations
of donepezil and idalopirdine were measured in a selection of an-
imals (indicated in Fig. 4) at the end of the recording, being 120min
after idalopirdine/vehicle treatment and 60 min after donepezil/
vehicle administration. At the terminal time point, a blood sample
was taken by heart puncture and kept in 1.6 mg EDTA/mL of blood.
Rats were euthanized by cervical dislocation as described previ-
ously, brains were dissected out and stored at 80 C until they
were sectioned at 20 mm on a cryostat (CM3050S, Leica Biosystems,
UK) in serial coronal slices to inspect for electrode placement. Blood
samples were centrifuged for 10 min at 5000 g at 4 C and plasma
was stored at 80 C until bioanalysis.
In the EEG study, compound exposure was not investigated as
animals were, for another purpose, monitored for a total of 24 h.
Compound concentrations at the terminal time point would not
reﬂect those during the EEG recordings.
2.3.2. Quantitative bioanalysis
Rat plasma and brain concentrations of idalopirdine and done-
pezil were determined using Ultra performance liquid chroma-
tography coupled to tandem mass spectrometry (MS/MS). Brain
homogenate samples were prepared by homogenizing the whole
brainwith 70% acetonitrile (1:4, v/v) followed by centrifugation and
collection of the supernatant. Plasma or brain samples (25 ml) were
precipitated with 150 ml acetonitrile containing internal standard.
For idalopirdine, 13C-labelled internal standard was used. After
centrifugation, 100 ml supernatant from each sample was trans-
ferred to a new plate andmixed with 100 ml 0.1% formic acid. After a
quick centrifugation the samples were placed in the autosampler.Chromatography was performed on a Waters Aqurity C18 SB HSS
column (30  2.1 mm, 1.8 mm particles) using a mobile phase
gradient of 0.1% formic acid in water and acetonitrile pumped
through the column with a ﬂow rate of 0.6 ml/min. The retention
times were 1.13 and 0.93 min for idalopirdine and donepezil
respectively. MS/MS detection was performed with an Applied
Biosystems Sciex API 4000 instrument in positive-ion electrospray
ionization mode (AB Sciex, Foster City, CA). Mass to charge ratios
(m/z) of 399.1 > 221.1 and 380.2 > 91.2 were used for detection of
idalopirdine and donepezil, respectively. Nitrogen was used for the
nebulizer and collision gases. The peak area correlated linearly with
the concentration in the range of 0.5e1000 ng/ml in plasma and
2.5e5000 ng/g in brain for both analytes. Data acquisition and
analysis was performed using Analyst software, version 6.1 (AB
Sciex, Foster City, CA).
2.3.3. Data analysis
Plasma and brain concentrations of the compounds were
analyzed by a Kruskall-Wallis test followed by Dunn's post-hoc test
using SigmaPlot (version 11.0).
3. Results
3.1. The effect of idalopirdine in combination with donepezil on
gamma rhythm during nPO stimulation in the anesthetized rat
3.1.1. Effect of electrical stimulation of the nPO on oscillatory
activity in the mPFC
To establish baseline amplitude levels, a stimulation input/
output (I/O) curve was determined at the beginning of every
experiment. Increasing stimulation intensity was closely correlated
with increases in amplitude of gamma rhythm in the mPFC in rats.
The average intensity of all experiments to elicit 50% of the
maximal gamma amplitude under control conditions was
46 mA ± 15 (data not shown, see Supplementary Fig. 1 for a repre-
sentative experiment). No correlation was found between stimu-
lation intensity and gamma frequency.
Electrical stimulation of the nPO signiﬁcantly suppressed low
frequency delta (0e4 Hz) and theta (4e8 Hz) oscillations (Wilcoxon
singed rank test, p < 0.001) replacing them with high frequency
gamma oscillations (30e90 Hz) (Wilcoxon singed rank test,
p < 0.001) in the mPFC (Fig. 1A).
Systemic administration of the vehicles (glucose 5% and saline
0.9%, 1 ml/kg i.v.) did not signiﬁcantly affect any frequency rhythms
and therefore, the data from the vehicle group were used as control
(Fig. 1B). There were no treatment effects on oscillations pre-
stimulation (Fig. 2, left panel), therefore compound effects are
described during nPO stimulation (Fig. 2, right panel and Fig. 3).
3.1.2. Effect of idalopirdine on gamma power in the mPFC during
nPO stimulation
Idalopirdine dose-dependently increased gamma power during
electrical stimulation of the nPO when compared to vehicle treat-
ment during the ﬁrst 30 min after administration (F
[treatment  time]32,652 ¼ 1.968, p < 0.01, F
[treatment]2,652 ¼ 2.839, p ¼ 0.071, F[time]16,652 ¼ 1.485, p ¼ 0.100,
Fig. 3A). Idalopirdine 1 mg/kg i.v. did not signiﬁcantly increase
gamma power as compared to vehicle treatment. In contrast, ida-
lopirdine 2 mg/kg i.v. signiﬁcantly increased gamma power as
compared to vehicle treatment between 18 and 22 min after
administration, and as compared to idalopirdine 1mg/kg treatment
at the time points indicated in Fig. 3A (p < 0.05). Gamma power
peaked at ~150% of the baseline following treatment with idalo-
pirdine 2 mg/kg.
In addition, idalopirdine 2 mg/kg slightly decreased low
Fig. 2. Effect of idalopirdine, donepezil and the combination before and during nPO stimulation on the spectral power of oscillations in the mPFC of the anesthetized rat.
Effects of the treatments on oscillations (Hz) in the mPFC as a function of time (min); pre-stimulation (left column) and during nPO stimulation (right column). Each heatmap is
plotted with 1 Hz resolution (y-axis). nPO stimulations were repeated every 100 s and each vertical time bin in a heatplot represents the average spectral power of one such epoch,
either pre-nPO (5e0 s) or during nPO stimulation (1e6 s). Idalopirdine 1 or 2 mg/kg i.v. (IDL1 or IDL2) or vehicle (veh) were administered at time 0, donepezil 0.3 or 1 mg/kg i.v.
(DPZ1 or DPZ0.3) or veh at time 60. Heatplots show the average spectral power of each treatment group (n ¼ 6e8) standardized to the baseline period before drug or vehicle
administration (30e0 min relative to 1st injection).
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during electrical stimulation of the nPO as compared to vehicle
treatment during the ﬁrst 30 min after administration (delta: F
[treatment  time]32,652 ¼ 0.703, p ¼ 0.890, F
[treatment]2,652 ¼ 4.28, p < 0.05, F[time]16,652 ¼ 0.573, p ¼ 0.904;
theta: F[treatment  time]32,652 ¼ 0.593, p ¼ 0.964, F
[treatment]2,652 ¼ 3.697, p < 0.05, F[time]16,652 ¼ 0.566, p ¼ 0.910).
3.1.3. Effect of donepezil on gamma power in the mPFC during nPO
stimulation
Donepezil increased gamma power during nPO stimulation
when compared to vehicle treatment in the 60 min after admin-
istration (F[treatment  time]68,658 ¼ 1.488, p < 0.05, F[treatment]2,658 ¼ 3.200, p¼ 0.066, F[time]34,658¼ 1.128, p¼ 0.287,
Fig. 3B). At isolated time points, both doses of donepezil (0.3 and
1 mg/kg, i.v.) signiﬁcantly increased gamma power as compared to
vehicle treatment (p < 0.05, Fig. 3B) but overall no treatment effect
was reached. This occurred earlier following treatment with
donepezil 0.3 mg/kg (between 8 and 25 min after administration)
than for donepezil 1 mg/kg (between 20 and 46 min). Gamma
power peaked at ~140% of the baseline following treatment with
either dose of donepezil, however this response was maintained
longer with the 1 mg/kg as compared to the 0.3 mg/kg dose (46 vs.
25 min after administration, respectively). There was no statisti-
cally signiﬁcant difference between donepezil 0.3 and 1 mg/kg
treatment. No further potentiation of gamma power was obtained
Fig. 3. Effect of idalopirdine, donepezil and the combination on gamma power during nPO stimulation in the mPFC of the anesthetized rat. Effects of the treatments on
gamma (30e90 Hz) power in the mPFC. Data are presented as mean power relative to the 30 min baseline (%) ± SEM. Idalopirdine (IDL) or vehicle (veh) were administered at time 0,
donepezil (DPZ) or veh at time 60. (A) Dose response of idalopirdine (1 and 2 mg/kg i.v.). *p < 0.05 vs. veh or # vs. IDL1. (B) Dose response of donepezil (0.3 mg/kg and 1 mg/kg i.v.).
*p < 0.05 vs. veh/veh. (C) Donepezil at the low dose (0.3 mg/kg i.v.) in combination with idalopirdine (1 and 2 mg/kg i.v.). *p < 0.05 vs. veh/veh or # vs. veh/DPZ0.3. (D) Donepezil at
the high dose (1 mg/kg i.v.) in combination with idalopirdine (2 mg/kg i.v.). *p < 0.05 vs. veh/veh or # vs. veh/DPZ1.
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stimulation intensity (data not shown). Lower frequency oscilla-
tions were not signiﬁcantly affected by donepezil treatment
(p > 0.05).3.1.4. Effect of idalopirdine in combination with donepezil on
gamma power in the mPFC during nPO stimulation
Idalopirdine signiﬁcantly potentiated and/or prolonged the ef-
fect of the low dose of donepezil (0.3 mg/kg) on gamma power
during nPO stimulation in the 60 min after donepezil administra-
tion (F[treatment]3,948 ¼ 6.732, p < 0.01, F[time]34,948 ¼ 3.685,
p < 0.001, F[treatment  time]102,948 ¼ 1.449, p < 0.01, Fig. 3C).
Idalopirdine 2 mg/kg in combination with donepezil 0.3 mg/kg
signiﬁcantly increased gamma power as compared to vehicle
treatment (overall treatment effect: p < 0.01), while there was no
signiﬁcant overall effect of donepezil 0.3 mg/kg alone. The response
to idalopirdine 2 mg/kg in combination with donepezil 0.3 mg/kg
was signiﬁcantly different from vehicle treatment from 8 to 40 min
after donepezil administration (p < 0.05), peaking at ~180% of
baseline and plateauing at ~150% for the rest of the recording
period. In contrast, the response to donepezil 0.3 mg/kg alone
transiently peaked at ~140% of baseline. Thus, idalopirdine 2 mg/kg
potentiated and prolonged the effects of donepezil 0.3 mg/kg on
gamma power.
Also idalopirdine 1 mg/kg in combination with donepezil
0.3 mg/kg signiﬁcantly increased gamma power as compared to
vehicle treatment from 5 to 22 min after donepezil administration
(p < 0.05) and potentiated the effect of donepezil 0.3 mg/kg aloneduring the peak effect, 8e10 min after administration (p < 0.05).
The response to idalopirdine 1 mg/kg in combination with done-
pezil 0.3 mg/kg peaked at ~200% of the baseline, not being signif-
icantly different from the peak effect observed with idalopirdine
2 mg/kg in the combination treatment (~180%). However, the effect
of idalopirdine 1 mg/kg was not sustained throughout the
recording period as was observed with idalopirdine 2 mg/kg. Thus,
whereas both doses of idalopirdine (1 and 2mg/kg) potentiated the
effects of donepezil 0.3 mg/kg on gamma power, the effect of ida-
lopirdine 1 mg/kg was transient whereas the effect of idalopirdine
2 mg/kg was sustained throughout the recording period.
Idalopirdine 2 mg/kg also signiﬁcantly potentiated the effect of
the high dose of donepezil (1 mg/kg) on gamma power during nPO
stimulation in the 60 min after donepezil administration (F
[treatment  time]68,623 ¼ 2.035, p < 0.001, F
[treatment]2,623 ¼ 4.648, p¼ 0.026, F[time]34,623 ¼ 1.471, p¼ 0.045,
Fig. 3D). Idalopirdine 2 mg/kg in combinationwith donepezil 1 mg/
kg signiﬁcantly increased gamma power as compared to vehicle
treatment (overall treatment effect: p < 0.05) and as compared to
donepezil 1 mg/kg alone at selected time points indicated in Fig. 3D
(p < 0.05). The response to idalopirdine 2 mg/kg in combination
with donepezil 1 mg/kg was signiﬁcantly different from vehicle
treatment from 15 to 45 min after donepezil administration
(p < 0.05) peaking at ~180% of the baseline, not decreasing below
~150% during the signiﬁcant period. In contrast, the response to
donepezil 1 mg/kg alone peaked and plateaued at ~140%. Thus,
idalopirdine 2 mg/kg potentiated the effects of donepezil 1.0 mg/kg
on gamma power.
M. Amat-Foraster et al. / Neuropharmacology 113 (2017) 45e5952Analysis of the different treatments over time as compared to
vehicle treatment revealed that none of the treatments signiﬁ-
cantly modulated the power of other frequency bands (p > 0.05).
3.1.5. Plasma and brain exposure of idalopirdine and donepezil in
the nPO stimulation assay
In the nPO stimulation assay, plasma and brain concentrations
of idalopirdine and donepezil were determined in a selection of
animals at the end of the recording, 120 min after idalopirdine
treatment and at 60 min after donepezil treatment, respectively
(Fig. 4). Donepezil concentrations in plasma (H ¼ 21.82, p < 0.001)
and brain (H ¼ 18.61, p < 0.001) increased in a dose-dependent
manner, being higher following treatment with donepezil 1 mg/
kg i.v. as compared to 0.3 mg/kg i.v. (at least p < 0.05 for selected
groups, indicated in Fig. 4A and B). There was no signiﬁcant effect of
idalopirdine (1 or 2 mg/kg, i.v.) pretreatment on donepezil con-
centrations at either dose of donepezil.
Idalopirdine concentrations increased in a dose-dependent
manner in both plasma (H ¼ 15.24, p < 0.001) and brain
(H ¼ 12.68, p < 0.001) and were signiﬁcantly higher in the groups
receiving idalopirdine 2 mg/kg i.v. as compared to 1 mg/kg i.v. (at
least p < 0.05, Fig. 4C and D). There was no signiﬁcant effect of
donepezil (0.3 vs. 1 mg/kg i.v.) on the concentration of idalopirdine
(2 mg/kg i.v.) in plasma and brain.
3.2. The effect of idalopirdine in combination with donepezil on
gamma rhythm in the frontal cortex in freely moving rats
Given the treatment effects on gamma power in the nPO stim-
ulation assay, we investigated the effect of idalopirdine, donepezil
and the combination on cortical gamma oscillations in freely-
moving rats. There was no change in locomotor activity as
measured by the DSI transmitter in any of the treatment groups forFig. 4. Terminal plasma and brain concentrations of idalopirdine and donepezil in
administered 60 min prior to donepezil 0.3 or 1.0 mg/kg i.v. (DPZ0.3 or DPZ1) or veh. Term
60 min after DPZ treatment, respectively. Data are represented as AVG plasma (ng/ml) and
p < 0.01 or p < 0.001 vs. DPZ0.3/IDL1, #p < 0.05 vs. DPZ0.3/IDL2 (C) IDL in plasma, (D) IDLthe times tested (data not shown, ANOVA, F25,1860 ¼ 0.888,
p¼ 0.623). Gamma spectral power (30e90 Hz), investigated during
active wake, is represented in the heatplots (Fig. 5) and quantiﬁed
for each 30 min bin from 90 min before the ﬁrst treatment (base-
line) to 120 min after the second treatment (Fig. 6). Idalopirdine
(10 mg/kg p.o.) alone had no effect on gamma power during the
120 min period after administration. Donepezil, administered 2 h
after idalopirdine or vehicle, dose-dependently increased gamma
power in the 120 min period after administration (F
[treatment]5,164 ¼ 15.378, p < 0.001, F[time]3,164 ¼ 4.123, p < 0.01, F
[treatment  time]15,164 ¼ 5.115, p < 0.001, Fig. 6). Both donepezil
1 mg/kg and 3 mg/kg s.c. increased gamma power as compared to
vehicle treatment (p < 0.05 and p < 0.001, respectively) and gamma
power was further increased by 3 mg/kg as compared to 1 mg/kg
donepezil (p < 0.05). Idalopirdine (10 mg/kg) signiﬁcantly poten-
tiated the effect of donepezil 1 mg/kg on gamma power (p < 0.05),
whereas there was no further potentiation of the response to
donepezil 3 mg/kg by idalopirdine (p ¼ 0.502).
In addition, donepezil (1 and 3 mg/kg s.c.) alone signiﬁcantly
decreased alpha power as compared to vehicle treatment (p < 0.05)
in the 120 min period after administration, while idalopirdine
(10 mg/kg p.o.) alone had no effect (F[treatment]5,164 ¼ 5.159,
p < 0.001, F[time]3,164 ¼ 3.873, p < 0.05, F
[treatment  time]15,164 ¼ 0.620, p ¼ 0.853, Supplementary Fig. 2).
There was no statistically signiﬁcant difference between the two
doses of donepezil. Idalopirdine (10mg/kg p.o.) in combinationwith
donepezil 1 mg/kg did not result in a signiﬁcant decrease in alpha
power as compared to vehicle treatment, suggesting that pretreat-
mentwith idalopirdineattenuates theeffectof donepezil 1mg/kgon
alpha power. In contrast, pretreatment with idalopirdine did not
modulate the effect of donepezil 3 mg/kg on alpha power.
Analysis of the different treatments over time as compared to
vehicle treatment revealed that none of the treatmentsthe nPO assay. Idalopirdine 1 or 2 mg/kg i.v. (IDL1 or IDL2) or vehicle (veh) were
inal plasma and brain samples were collected at 120 min after IDL treatment and at
brain (ng/g) concentrations ± SEM (A) DPZ in plasma, (B) DPZ in brain. *,**,***p < 0.05,
in brain. *,**,***p < 0.05, p < 0.01 or p < 0.001 vs. IDL1/DPZ0.3. ns ¼ non signiﬁcant.
Fig. 5. Effect of idalopirdine, donepezil and the combination on the spectral power of gamma oscillations in the frontal cortical EEG of the freely moving rat. Effects of the
treatments on gamma oscillations (Hz) in the frontal cortical qEEG during active wake as a function of time (min). Each heatmap is plotted with 1 Hz resolution (y-axis). Idalopirdine
10 mg/kg p.o. (IDL) or vehicle (veh) were administered at time 0, donepezil 1 or 3 mg/kg s.c. (DPZ1 or DPZ3) or veh at time 120. Each horizontal time bin in a heatplot represents the
average spectral power per 30 min time bin. Heatplots show the average spectral power of each treatment group (n ¼ 7e9) normalized to the baseline period before drug or vehicle
administration (90e0 min relative to the 1st injection).
Fig. 6. Effect of idalopirdine, donepezil and the combination on frontal cortical
gamma power in the EEG of the freely moving rat. Effects of the treatments on
gamma (30e90 Hz) power in the frontal cortical qEEG during active wake as a function
of time (min). Data are presented as mean power per 30 min time bin relative to the
90 min baseline (%) ± SEM (n ¼ 7e9). Idalopirdine 10 mg/kg p.o. (IDL) or vehicle (veh)
were administered at time 0, donepezil 1 or 3 mg/kg s.c. (DPZ1 or DPZ3) or veh at time
120. *p < 0.05 vs. veh/veh or # vs. veh/DPZ1 (time ¼ 150e240 min).
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(p > 0.05).3.3. The effect of idalopirdine in combination with donepezil on
sleep-wake patterns in freely moving rats
Donepezil dose-dependently delayed the onset of REM sleep (F
[treatment]5,47 ¼ 49.59, p < 0.0001, Table 1). Both doses of done-
pezil delayed REM onset as compared to vehicle treatment (p< 0.05
and p < 0.001 for donepezil 1 and 3 mg/kg s.c., respectively) and
REM onset was further delayed following treatment with donepezil
3 mg/kg as compared to 1 mg/kg (p < 0.001). Donepezil 3 mg/kg
also delayed the onset of NREM sleep (F[treatment]5,47 ¼ 26.61,
p < 0.0001, Table 1) in comparison to both vehicle (p < 0.001) and
donepezil 1 mg/kg (p < 0.001). Idalopirdine (10 mg/kg, p.o.) did not
modulate the onset of REM or NREM sleep, nor the effects of
donepezil (Table 1).
The donepezil-induced delay in onset of sleep was paralleled by
a reduction in time spent in both sleep stages during the 120 min
following donepezil administration (REM: F[treatment]5,47¼ 36.04,
p < 0.0001, NREM: F[treatment]5,47 ¼ 56.64, p < 0.0001, Fig. 7A and
B). Both doses of donepezil reduced the time spent in REM and
NREM sleep as compared to vehicle treatment (p < 0.001) and
donepezil 3 mg/kg further reduced the time spent in both REM and
NREM sleep in comparison to donepezil 1 mg/kg (p < 0.05 and
Table 1
Effect of idalopirdine, donepezil and the combination on the onset of REM and NREM sleep in the freely moving rat.
Treatment VEH/VEH IDL/VEH VEH/DPZ1 IDL/DPZ1 VEH/DPZ3 IDL/DPZ3
REM 47 ± 4 45 ± 5 98 ± 20* 125 ± 21** 232 ± 5**,## 238 ± 2**,##
NREM 31 ± 3 31 ± 3 48 ± 4 51 ± 5 169 ± 18**,## 154 ± 22**,##
Effects of the treatments on the onset of REM and NREM sleep. Idalopirdine (IDL) or vehicle (veh) were administered 120 min prior to donepezil (DPZ) or veh. Onset was
deﬁned as the ﬁrst epoch of REM or NREM, lasting greater than 20 s following the 2nd treatment. Data are represented as AVG time (min) after the 2nd treatment ± SEM
(n ¼ 7e9). *, **p < 0.05 or p < 0.001 vs. VEH/VEH, ##p < 0.001 vs DPZ1 with similar pretreatment.
Fig. 7. Effect of idalopirdine, donepezil and the combination on sleep-/wake architecture in the freely moving rat. Effects of the treatments on REM and NREM sleep, quiet and
active wake. Idalopirdine 10 mg/kg p.o. (IDL) or vehicle (veh) were administered 120 min prior to donepezil 1 or 3 mg/kg (DPZ1 or DPZ3) or veh. Data are represented as AVG time
spent (%) in each phase in the 120 min after the 2nd treatment ± SEM (n ¼ 7e9). *, **p < 0.05 or p < 0.001 vs. VEH/VEH, #, ## p < 0.05 or p < 0.001 vs DPZ1 with similar pre-
treatment. ns ¼ non-signiﬁcant.
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did not modulate the percentage of time spent in REM or NREM
sleep, nor the effect of either dose of donepezil (Fig. 7A and B).
Conversely, donepezil dose-dependently increased the time
spent in quiet wake (F[treatment]5,47 ¼ 68.08, p < 0.0001, Fig. 7C).
Both doses of donepezil increased the time spent in quiet wake as
compared to vehicle treatment (p < 0.001) and donepezil 3 mg/kg
further increased the time spent in quiet wake in comparison to
donepezil 1 mg/kg (p < 0.001). Idalopirdine (10 mg/kg) did not
modulate the percentage of time spent in quiet wake, nor the ef-
fects of donepezil (Fig. 7C). There were no treatment effects on
active wake, with the exception of an increase observed in the
donepezil 1 mg/kg group (F[treatment]5,47 ¼ 2.967, p < 0.05,
Fig. 7D).
4. Discussion
In the present study we demonstrate that treatment with the 5-
HT6 receptor antagonist idalopirdine (Lu AE58054) alone enhanced
cortical gamma power under strong afferent drive, but further, withthe AChEI donepezil present, enhanced gamma power to a greater
extent than either cholinesterase inhibition or 5-HT6 antagonism
alone. In contrast, idalopirdine did not affect sleep-wake architec-
ture nor did it modify the effects of donepezil. We discuss in the
context of two in vivo electrophysiological assays, neuronal oscil-
lations during nPO stimulation in the anesthetized rat and sleep-
stage controlled qEEG in the freely-moving rat, the effects of
donepezil, idalopirdine and the combination of both on cortical
excitability and on sleep-wake architecture.
4.1. Effects of donepezil, idalopirdine and the combination on
oscillatory activity in the mPFC during stimulation of the nPO
In anesthetized rats, high frequency stimulation of the brain-
stem nPO evoked gamma oscillations and reduced delta and theta
oscillations in the mPFC. This ﬁnding is consistent with previous
reports showing that stimulation of various nuclei of the reticular
formation suppresses low frequency oscillations replacing them
with high frequency oscillations in the cortex (Dringenberg and
Olmstead, 2003; Wu et al., 2007).
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cillations in rat hippocampal slices (Spencer et al., 2010) and in the
hippocampus of the anesthetized rat during electrical stimulation
of the nPO (Herrik et al., 2016). To our knowledge, this is the ﬁrst
study showing that a procognitive drug, donepezil (0.3 and 1.0 mg/
kg i.v.), selectively augments gamma oscillations in the mPFC dur-
ing nPO stimulation under urethane anesthesia, suggesting that
stimulation-induced cortical gamma oscillations are sensitive to
procognitive compounds. However, the effects of donepezil may
have a ceiling effect, as demonstrated by Spencer et al. for
donepezil-induced gamma oscillations in hippocampal slices
(Spencer et al., 2010). This is supported by the ﬁndings in our nPO
assay, as the peak response to both doses of donepezil was similar
(~140% of baseline), though maintained longer with donepezil 1 as
compared to 0.3 mg/kg. Furthermore, increasing the dose of
donepezil beyond 1 mg/kg did not further increase gamma power
in the mPFC (data not shown). Yet, the efﬁcacy of both doses of
donepezil (0.3 and 1 mg/kg) to increase cortical gamma oscillations
was further potentiated by pretreatment with the 5-HT6 receptor
antagonist idalopirdine. We previously demonstrated that done-
pezil at the dose of 0.3mg/kg i.v. results in plasma concentrations in
the clinically relevant range in the time frame where oscillatory
activity peaks, and that these are not altered by pretreatment with
idalopirdine (Herrik et al., 2016). In the current study, we conﬁrmed
that plasma and brain exposure of donepezil were not modulated
by co-administration of idalopirdine. Thus, we conclude that, in the
nPO model, idalopirdine potentiates the effects of clinically rele-
vant concentrations of donepezil on gamma oscillations in the
mPFC. Similarly, we have recently shown that idalopirdine poten-
tiates and prolongs the effects of donepezil on theta and gamma
power during nPO stimulation in the hippocampus of the rat
(Herrik et al., 2016). These parallel treatment effects in the hippo-
campus and mPFC support the coherence in oscillatory activity
observed between the dorsal hippocampus and the mPFC during
nPO stimulation (Kiss et al., 2013) and synchronization of network
activity between these two brain regions is likely to play a role
during performance of a cognitive task (Jones and Wilson, 2005;
Kiss et al., 2013).
Interestingly, idalopirdine (2 mg/kg i.v.) as a monotherapy also
increased the effect of nPO stimulation by increasing gamma power
and slightly reducing slower oscillations (1e8 Hz) in themPFC, with
an increase in gamma power of a similar magnitude to that of
donepezil alone (~150 vs. ~140%). This indicates that both 5-HT6
receptor antagonism and cholinesterase inhibition can indepen-
dently facilitate oscillatory activity in the mPFC in this assay.
Moreover, higher peak responses were obtained with the combi-
nation of idalopirdine 2 mg/kg with either dose of donepezil
(~180%), indicating that the effects of both compounds are, at least
partially, cumulative. Whether there is a synergy between both
mechanisms or whether the effects of both treatments are additive,
cannot be concluded from the present data, but earlier observations
that 5-HT6 receptor antagonists potentiate the effects of donepezil
on ACh levels are suggestive of an, at least partially, synergistic
mechanism (Dawson, 2011; Herrik et al., 2016). Interestingly, only
the high dose of idalopirdine (2 mg/kg i.v.) increased gamma os-
cillations as a monotherapy. Furthermore, whilst both doses of
idalopirdine (1 and 2mg/kg i.v.) potentiated the effects of donepezil
0.3 mg/kg on gamma power, only with the high dose (2 mg/kg i.v.)
was this effect sustained throughout the recording period. At the
2 mg/kg i.v. dose, idalopirdine concentrations were around 100 ng/
ml in plasma which is well above previously reported plasma
concentration of 20 ng/ml leading to 50% occupancy of the 5-HT6
receptors in vivo in rats (Arnt et al., 2010). The minimally required
receptor occupancy is not precisely known but it is assumed that
quite high 5-HT6 receptor occupancy, above 60%, is required for theprocognitive effects (Arnt et al., 2010).
4.2. Effects of donepezil, idalopirdine, and the combination on
oscillatory activity in the frontal cortex in awake spontaneous qEEG
Also in the awake freely moving rat, donepezil (1 and 3 mg/kg
s.c.) dose-dependently enhanced cortical gamma power, an
observation which is consistent with the previously published
report by Ahnaou and colleagues (Ahnaou et al., 2014). Further-
more, in line with our ﬁndings in the nPO stimulation model,
idalopirdine (10 mg/kg p.o.) pretreatment further potentiated the
effects of donepezil 1 mg/kg on gamma power in the frontal
cortex. In contrast, the effect of donepezil 3 mg/kg on gamma
power was not further potentiated by idalopirdine and at this dose
of donepezil a ceiling in the gamma response may have been
reached.
In exposure studies (data not shown), we established that the
dose of 1 mg/kg s.c. donepezil resulted in plasma concentrations
within the clinically relevant range (50e100 ng/ml up to 2 h after
administration) (Tiseo et al., 1998), whereas concentrations above
the therapeutic range were obtained with donepezil 3 mg/kg
(250 ng/ml) (Tiseo et al., 1998; Gomolin et al., 2011). It is therefore
concluded that idalopirdine increases the effect of a clinically
relevant concentration of donepezil on frontal cortical gamma
power in the EEG of the freely moving rat.
Interestingly, although idalopirdine (2 mg/kg i.v.) acted as a
monotherapy and increased cortical gamma in the nPO assay,
idalopirdine (10 mg/kg, p.o.) did not elicit an increase in cortical
gamma in the spontaneous qEEG of awake freely-moving rats,
despite the fact that high receptor occupancy in the brain was
achieved in both assays (Arnt et al., 2010; Herrik et al., 2016). The
different placement of the electrodes in these two assays could
partly explain the differential effects observed with idalopirdine
alone. In addition, this discrepancy could be explained by the fact
that in the EEG study, rats were in their home cage and although
awake and exploring their environment, they were not receiving
any particularly salient or cognition-demanding cues. In contrast,
electrical stimulation of the nPO would provide an inherent drive
to cortical afferents, encompassing excitatory input from the
hippocampus and thalamocortical projections (Thierry et al.,
2000; Steriade, 1999). Thus, we propose that it is under this
higher afferent (signal) load that 5-HT6 receptor antagonism
functions to increase signal-to-noise as a monotherapy (Pinault,
2014). In the case of the spontaneous EEG, there may not be suf-
ﬁcient afferent drive to reveal this monotherapy effect. However,
in the presence of donepezil, the cholinergic system is able to
enhance thalamocortical drive to the cortical afferents, as thala-
mocortical inputs in the sensory cortex were shown to be facili-
tated in an ACh concentration-dependent manner (Dringenberg
et al., 2007; Deco and Thiele, 2011; Kang et al., 2014). We pro-
pose that under this greater afferent activation mediated by
donepezil, the 5-HT6 receptor antagonist idalopirdine now po-
tentiates this effect. The potential mechanisms are discussed in
greater detail below.
Analogous to the observations by Ahnaou et al., 2014, donepezil
(1 and 3 mg/kg s.c.) decreased cortical alpha power in the spon-
taneous qEEG of awake freely-moving rats. Idalopirdine (10 mg/kg
p.o.) attenuated this decrease in cortical alpha power at the low
dose of donepezil (1 mg/kg s.c.), while it did notmodulate the effect
of the high dose of donepezil (3 mg/kg s.c.). Alpha frequency,
although the ﬁrst frequency characterized, seems to be the most
complicated in interpretation and identifying its generators or
sources. In addition, there are fundamental differences between
rodent and man in alpha rhythm (Shaw, 2013). Therefore, the im-
plications of these changes in cortical alpha activity require further
M. Amat-Foraster et al. / Neuropharmacology 113 (2017) 45e5956investigation.
4.3. The role of 5-HT6 receptor antagonism in cortical excitability
There are several possible mechanisms through which 5-HT6
receptor antagonism may modulate cortical gamma oscillations.
We have recently demonstrated that idalopirdine potentiates the
effect of donepezil on extracellular levels of ACh in both the hip-
pocampus and the mPFC of the rat (Foraster et al., 2014; Herrik
et al., 2016), which is in agreement with two other studies
showing that 5-HT6 receptor antagonism potentiates cholinergic
signaling in the PFC (Riemer et al., 2003; Hirst et al., 2006). The
cholinergic system is known to be crucial for triggering theta and
gamma oscillations in the hippocampus and cortex. For example,
gamma oscillations can be induced in hippocampal and cortical
slice preparations by cholinergic receptor activationwith carbachol
and with the AChEIs physostigmine and donepezil (Buhl et al.,
1998; Traub et al., 2000; Fellous and Sejnowski, 2000; Spencer
et al., 2010; Pietersen et al., 2014). Furthermore, nicotine and the
AChEI neostigmine have been shown to induce gamma oscillations
in the hippocampus in vivo (Joosen and van Helden, 2007; Phillips
et al., 2007; Ahnaou et al., 2014). We therefore propose that by
locally increasing the levels of ACh in the frontal cortex, idalo-
pirdine may potentiate the effects of donepezil on gamma oscilla-
tory activity in this brain region.
The cellular localization of the 5-HT6 receptor provides further
insight into the potential mechanism through which idalopirdine
facilitates neuronal oscillations. We have recently demonstrated
that 5-HT6 receptor mRNA is expressed by pyramidal cells
throughout the cortical regions and in the hippocampus as well as
by a subset of GABA-ergic interneurons (approximately 15%), the
majority of which belonged to the 5-HT3a receptor-expressing
subpopulation. A subset of calbindin (CB)- and calretinin (CR)-
positive GABA-ergic interneurons also expressed 5-HT6 receptor
mRNA (Helboe et al., 2015). Gamma oscillations are driven by
phasic inhibition from GABA-ergic interneurons that modulate
activity of excitatory glutamatergic pyramidal neurons (Cardin
et al., 2009; Traub et al., 1999; Whittington et al., 1995). The
commonly accepted origin of inhibition underlying gamma
rhythms is the fast spiking, perisomatic targeting, parvalbumin (PV)
positive basket cell (Cardin et al., 2009; Gulyas et al., 2010) and
gamma rhythms resulting from synchronization of PV fast spiking
interneurons have been linked to PFC-dependent cognitive ﬂexi-
bility and attention (Cho et al., 2015; Kim et al., 2016). However, PV
positive interneurons are nearly devoid of 5-HT6 receptor mRNA
(Helboe et al., 2015). Interestingly, 5-HT3a expressing interneurons
were shown to modulate gamma oscillations in the hippocampus
by regulating synchrony of PV fast spiking interneurons and ida-
lopirdine may facilitate gamma oscillations through modulation of
this cell type (Huang et al., 2014). Later studies have shown the
involvement of multiple types of interneurons in the generation of
cortical gamma rhythms (Whittington et al., 2011) and it will be of
great future interest to study the speciﬁc contributions of 5-HT3a
receptor, CR and CB positive interneurons as well as pyramidal
neurons, to the effects of idalopirdine on neuronal oscillations and
cognition.
4.4. Effects of donepezil, idalopirdine, and the combination on
sleep-wake architecture in the freely moving rat
Donepezil dosed at the beginning of the light cycle, during
which nocturnal animals sleep, dose-dependently promoted
wakefulness by delaying the onset of sleep and, as a consequence,
reducing the time spent in both NREM and REM sleep stages. These
ﬁndings are in agreement with an earlier study with donepezil inthe freely moving rat (Ishida and Kamei, 2009). Also in AD patients,
insomnia and other sleep disorders (abnormal dreams, vivid
dreams and nightmares) have been reported following the
administration of donepezil (Rogers et al., 1998; Wilkinson, 1999;
Burns et al., 1999; Jackson et al., 2004). It has been proposed that
these effects are related to the exposure of the compound during
the night time and might be prevented by morning administration
(Jackson et al., 2004; Song et al., 2013). In contrast, donepezil has
also been suggested to enhance REM sleep in AD patients, which is
in agreement with the role of acetylcholine in promoting REM sleep
(Ringman and Simmons, 2000; Moraes et al., 2006). The reduction
in both NREM and REM sleep observed with donepezil in the cur-
rent study reﬂects the increased latency to sleep and does not allow
for further conclusions on the quality or nature of sleep.
The serotonergic system is also well recognized for its role in
sleep regulation, although the contribution of the 5-HT6 receptor is
not well investigated. Two studies have demonstrated that 5-HT6
receptor agonism promotes wakefulness in the rat (Monti et al.,
2013; Ly et al., 2013), whereas 5-HT6 receptor antagonism was re-
ported to either promote sleep (Morairty et al., 2008), increase
wakefulness (Monti et al., 2013) or have no effect (Ly et al., 2013).
Here we demonstrate that idalopirdine alone does not affect sleep-
wake architecture in the freely moving rat, in agreement with the
Ly study (Ly et al., 2013), and does not modulate the wake-
promoting effects of donepezil. The observation that idalopirdine
potentiates the effects of donepezil on cortical and hippocampal
excitability, but not on sleep, may be explained by the fact that 5-
HT6 receptor expression is very low in the brainstem regions that
mediate the sleep-wake cycle as compared to brain regions that
mediate cognition (Helboe et al., 2015).
4.5. Functional implications of the increase in cortical gamma
power
Antagonism of the 5-HT6 receptor appears a promising
approach for improving cognition, in particular for AD patients
(Ramirez, 2013; Wilkinson et al., 2014). The current study shows
that idalopirdine facilitates cortical gamma oscillations under
strong afferent drive and is able to augment donepezil's increase of
gamma power, without modifying the effects of donepezil on
sleep-wake architecture. Both cortical and hippocampal gamma
oscillations are involved in multiple aspects of cognitive and sen-
sory functions such as short-and long-term memory (Engel and
Singer, 2001; Kaiser et al., 2008; Kaiser and Lutzenberger, 2005;
Ainsworth et al., 2011; Herrmann et al., 2004; Pesaran et al.,
2002; Wu et al., 2008), selective attention (Doesburg et al., 2008;
Fries et al., 2001; Lakatos et al., 2008; Tallon-Baudry, 2009;
Womelsdorf et al., 2007; Womelsdorf and Fries, 2006), multisen-
sory integration (Lakatos et al., 2007) as well as memory refresh-
ment and formation and experience-dependent plasticity (Ward,
2003; Jutras and Buffalo, 2010; Fell and Axmacher, 2011; Headley
and Weinberger, 2011). In AD patients, a decrease in cortical
gamma power has been described, which can be partially reversed
by AChEI treatment (Babiloni et al., 2013; Herrmann et al., 2010). In
rodents, cognition enhancers have been shown to elicit cortical
gamma oscillations and coherent activity across different cortical
areas (Ahnaou et al., 2014), although compounds known to induce
cognitive impairment (i.e. ketamine) can induce robust increases in
state-independent gamma power (Pinault, 2008; Kittelberger et al.,
2012; Wood et al., 2012). Collectively, these observations suggest
that gamma oscillations are a useful efﬁcacy index for testing pu-
tative procognitive compounds. Therefore, the current observation
that idalopirdine enhances cortical excitability in the form of
gamma oscillations may represent one of the key mechanisms
through which 5-HT6 receptor antagonism exerts procognitive
M. Amat-Foraster et al. / Neuropharmacology 113 (2017) 45e59 57effects and may ultimately contribute to idalopirdine improving
cognitive function in donepezil-treated patients with AD
(Wilkinson et al., 2014).
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